{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T06:51:45Z","timestamp":1793170305777,"version":"4.5.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T00:00:00Z","timestamp":1774569600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T00:00:00Z","timestamp":1775692800000},"content-version":"vor","delay-in-days":13,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100017659","name":"Uniscientia Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100017659","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Mildred Scheel Career Center Frankfurt (Deutsche Krebshilfe) Frankfurt Cancer Institute"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Discov."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Glioblastoma (GB) is the most common primary malignant brain tumor in adults. Gboxin, a novel compound that targets oxidative phosphorylation via complex V inhibition, has shown promise in preclinical models of GB. We examined the efficacy of the pharmacokinetically optimized S-Gboxin under conditions replicating the GB microenvironment, including nutrient deprivation and hypoxia. We assessed cytotoxicity and growth-inhibitory effects of S-Gboxin in human GB cell lines, primary GB cultures, as well as immortalized and primary human astrocytes under different nutrient and oxygen deprivation scenarios. Oxygen consumption, cell migration, activation of the integrated stress response (ISR) as well as the relevance of the AMP-activated protein kinase (AMPK) were evaluated as variables under S-Gboxin treatment. S-Gboxin demonstrated cytotoxicity at low micromolar concentrations, with cell death enhanced under nutrient deprivation and hypoxia. S-Gboxin reduced cellular oxygen consumption and uncoupled mitochondria. Cytotoxicity was increased when mitochondrial fuels were the primary energy source. Additionally, S-Gboxin treatment resulted in elevated lactate production and glucose consumption. While the ISR marker ATF4 was induced by S-Gboxin in a dose-dependent manner, ISR inhibition with ISRIB did not affect its cytotoxicity. Conversely, S-Gboxin treatment combined with AMPK inhibition resulted in enhanced tumor cell death. Collectively, these findings demonstrate that S-Gboxin selectively targets cancer-specific metabolic vulnerabilities in GB cells. The synergistic action with AMPK inhibition suggests that this pathway contributes to maintain energy homeostasis in the presence of the drug. Therefore, S-Gboxin is a promising compound for GB therapy, especially in a combinatory approach with AMPK inhibition or other metabolic targeted therapies.<\/jats:p>","DOI":"10.1038\/s41420-026-03072-4","type":"journal-article","created":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T11:45:45Z","timestamp":1774611945000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Targeting glioblastoma mitochondrial metabolism with S-Gboxin induces cytotoxicity under conditions of the tumor microenvironment"],"prefix":"10.1038","volume":"12","author":[{"given":"Jan-B\u00e9la","family":"Weinem","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Urban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedikt","family":"Sauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanja","family":"Buhlmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4412-2355","authenticated-orcid":false,"given":"Ann-Christin","family":"Hau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Liebner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-4848-5464","authenticated-orcid":false,"given":"Tillmann","family":"Rusch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dmitry","family":"Namgaladze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leander F.","family":"Harwart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan-Hendrik","family":"Schr\u00f6der","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maeve","family":"de Souza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joachim P.","family":"Steinbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Legewie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna-Luisa","family":"Luger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1402-6290","authenticated-orcid":false,"given":"Michael W.","family":"Ronellenfitsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,27]]},"reference":[{"key":"3072_CR1","doi-asserted-by":"publisher","first-page":"iv1","DOI":"10.1093\/neuonc\/noad149","volume":"25","author":"QT Ostrom","year":"2023","unstructured":"Ostrom QT, Price M, Neff C, Cioffi G, Waite KA, Kruchko C, et al. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2016-2020. Neuro Oncol. 2023;25:iv1\u2013iv99.","journal-title":"Neuro Oncol"},{"key":"3072_CR2","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJMoa043330","volume":"352","author":"R Stupp","year":"2005","unstructured":"Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987\u201396.","journal-title":"N Engl J Med"},{"key":"3072_CR3","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.1038\/s43018-022-00475-x","volume":"3","author":"L Wang","year":"2022","unstructured":"Wang L, Jung J, Babikir H, Shamardani K, Jain S, Feng X, et al. A single-cell atlas of glioblastoma evolution under therapy reveals cell-intrinsic and cell-extrinsic therapeutic targets. Nat Cancer. 2022;3:1534\u201352.","journal-title":"Nat Cancer"},{"key":"3072_CR4","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.jocn.2018.05.002","volume":"54","author":"T Tykocki","year":"2018","unstructured":"Tykocki T, Eltayeb M. Ten-year survival in glioblastoma. A systematic review. J Clin Neurosci. 2018;54:7\u201313.","journal-title":"J Clin Neurosci"},{"key":"3072_CR5","volume":"14","author":"S Ravi","year":"2022","unstructured":"Ravi S, Alencar AM Jr., Arakelyan J, Xu W, Stauber R, Wang CI, et al. An update to hallmarks of cancer. Cureus. 2022;14:e24803.","journal-title":"Cureus"},{"key":"3072_CR6","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646\u201374.","journal-title":"Cell"},{"key":"3072_CR7","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1093\/neuonc\/now128","volume":"19","author":"H Lin","year":"2017","unstructured":"Lin H, Patel S, Affleck VS, Wilson I, Turnbull DM, Joshi AR, et al. Fatty acid oxidation is required for the respiration and proliferation of malignant glioma cells. Neuro Oncol. 2017;19:43\u201354.","journal-title":"Neuro Oncol"},{"key":"3072_CR8","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1038\/s41586-019-0993-x","volume":"567","author":"Y Shi","year":"2019","unstructured":"Shi Y, Lim SK, Liang Q, Iyer SV, Wang HY, Wang Z, et al. Gboxin is an oxidative phosphorylation inhibitor that targets glioblastoma. Nature. 2019;567:341\u20136.","journal-title":"Nature"},{"key":"3072_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2021.105780","volume":"171","author":"W Wu","year":"2021","unstructured":"Wu W, Klockow JL, Zhang M, Lafortune F, Chang E, Jin L, et al. Glioblastoma multiforme (GBM): an overview of current therapies and mechanisms of resistance. Pharmacol Res. 2021;171:105780.","journal-title":"Pharmacol Res"},{"key":"3072_CR10","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1113\/JP280572","volume":"599","author":"SJ Kierans","year":"2021","unstructured":"Kierans SJ, Taylor CT. Regulation of glycolysis by the hypoxia-inducible factor (HIF): implications for cellular physiology. J Physiol. 2021;599:23\u201337.","journal-title":"J Physiol"},{"key":"3072_CR11","doi-asserted-by":"publisher","first-page":"2515","DOI":"10.1016\/j.bbamcr.2016.02.012","volume":"1863","author":"L Biasutto","year":"2016","unstructured":"Biasutto L, Azzolini M, Szabo I, Zoratti M. The mitochondrial permeability transition pore in AD 2016: an update. Biochim Biophys Acta. 2016;1863:2515\u201330.","journal-title":"Biochim Biophys Acta"},{"key":"3072_CR12","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1093\/brain\/awp093","volume":"132","author":"MW Ronellenfitsch","year":"2009","unstructured":"Ronellenfitsch MW, Brucker DP, Burger MC, Wolking S, Tritschler F, Rieger J, et al. Antagonism of the mammalian target of rapamycin selectively mediates metabolic effects of epidermal growth factor receptor inhibition and protects human malignant glioma cells from hypoxia-induced cell death. Brain. 2009;132:1509\u201322.","journal-title":"Brain"},{"key":"3072_CR13","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.15252\/embr.201642195","volume":"17","author":"K Pakos-Zebrucka","year":"2016","unstructured":"Pakos-Zebrucka K, Koryga I, Mnich K, Ljujic M, Samali A, Gorman AM. The integrated stress response. EMBO Rep. 2016;17:1374\u201395.","journal-title":"EMBO Rep"},{"key":"3072_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-93663-1","volume":"11","author":"NI Lorenz","year":"2021","unstructured":"Lorenz NI, Sittig ACM, Urban H, Luger AL, Engel AL, Munch C, et al. Activating transcription factor 4 mediates adaptation of human glioblastoma cells to hypoxia and temozolomide. Sci Rep. 2021;11:14161.","journal-title":"Sci Rep"},{"key":"3072_CR15","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1038\/nrm3311","volume":"13","author":"DG Hardie","year":"2012","unstructured":"Hardie DG, Ross FA, Hawley SA. AMPK: a nutrient and energy sensor that maintains energy homeostasis. Nat Rev Mol Cell Biol. 2012;13:251\u201362.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"3072_CR16","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s13046-025-03346-2","volume":"44","author":"NI Lorenz","year":"2025","unstructured":"Lorenz NI, Sauer B, Urban H, Weinem JB, Parmar BS, Zeiner PS, et al. AMP-activated protein kinase mediates adaptation of glioblastoma cells to conditions of the tumor microenvironment. J Exp Clin Cancer Res. 2025;44:104.","journal-title":"J Exp Clin Cancer Res"},{"key":"3072_CR17","doi-asserted-by":"publisher","first-page":"884S","DOI":"10.3945\/ajcn.110.001917","volume":"93","author":"PJ Fernandez-Marcos","year":"2011","unstructured":"Fernandez-Marcos PJ, Auwerx J. Regulation of PGC-1alpha, a nodal regulator of mitochondrial biogenesis. Am J Clin Nutr. 2011;93:884S\u201390.","journal-title":"Am J Clin Nutr"},{"key":"3072_CR18","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.70030","volume":"14","author":"B Sauer","year":"2024","unstructured":"Sauer B, Kueckelhaus J, Lorenz NI, Bozkurt S, Schulte D, Weinem JB, et al. An AMP-activated protein kinase-PGC-1alpha axis mediates metabolic plasticity in glioblastoma. Clin Transl Med. 2024;14:e70030.","journal-title":"Clin Transl Med"},{"key":"3072_CR19","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.cell.2012.03.017","volume":"149","author":"M Laplante","year":"2012","unstructured":"Laplante M, Sabatini DM. mTOR signaling in growth control and disease. Cell. 2012;149:274\u201393.","journal-title":"Cell"},{"key":"3072_CR20","doi-asserted-by":"crossref","unstructured":"Heinzen D, Dive I, Lorenz NI, Luger AL, Steinbach JP, Ronellenfitsch MW. Second generation mTOR inhibitors as a double-edged sword in malignant glioma treatment. Int J Mol Sci. 2019;20:4474.","DOI":"10.3390\/ijms20184474"},{"key":"3072_CR21","doi-asserted-by":"crossref","unstructured":"Urban H, Maurer GD, Luger AL, Lorenz NI, Sauer B, Stroh C, et al. Cetuximab-mediated protection from hypoxia- induced cell death: implications for therapy sequence in colorectal cancer. Cancers. 2020;12:3050.","DOI":"10.3390\/cancers12103050"},{"key":"3072_CR22","doi-asserted-by":"publisher","first-page":"8233","DOI":"10.1038\/sj.onc.1207198","volume":"22","author":"J Wischhusen","year":"2003","unstructured":"Wischhusen J, Naumann U, Ohgaki H, Rastinejad F, Weller M. CP-31398, a novel p53-stabilizing agent, induces p53-dependent and p53-independent glioma cell death. Oncogene. 2003;22:8233\u201345.","journal-title":"Oncogene"},{"key":"3072_CR23","doi-asserted-by":"crossref","unstructured":"Evans AM, Hardie DG. AMPK and the need to breathe and feed: what\u2019s the matter with oxygen? Int J Mol Sci. 2020;21:3518.","DOI":"10.3390\/ijms21103518"},{"key":"3072_CR24","doi-asserted-by":"publisher","first-page":"3037","DOI":"10.1074\/jbc.RA118.006993","volume":"294","author":"I Bruns","year":"2019","unstructured":"Bruns I, Sauer B, Burger MC, Eriksson J, Hofmann U, Braun Y, et al. Disruption of peroxisome proliferator-activated receptor gamma coactivator (PGC)-1alpha reverts key features of the neoplastic phenotype of glioma cells. J Biol Chem. 2019;294:3037\u201350.","journal-title":"J Biol Chem"},{"key":"3072_CR25","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.biocel.2016.08.029","volume":"79","author":"AI Mot","year":"2016","unstructured":"Mot AI, Liddell JR, White AR, Crouch PJ. Circumventing the Crabtree Effect: a method to induce lactate consumption and increase oxidative phosphorylation in cell culture. Int J Biochem Cell Biol. 2016;79:128\u201338.","journal-title":"Int J Biochem Cell Biol"},{"key":"3072_CR26","doi-asserted-by":"publisher","first-page":"6060","DOI":"10.1111\/jcmm.14469","volume":"23","author":"L Chen","year":"2019","unstructured":"Chen L, He J, Zhou J, Xiao Z, Ding N, Duan Y, et al. EIF2A promotes cell survival during paclitaxel treatment in vitro and in vivo. J Cell Mol Med. 2019;23:6060\u201371.","journal-title":"J Cell Mol Med"},{"key":"3072_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-40280-3","volume":"14","author":"Y Zou","year":"2023","unstructured":"Zou Y, Sun Y, Wang Y, Zhang D, Yang H, Wang X, et al. Cancer cell-mitochondria hybrid membrane coated Gboxin loaded nanomedicines for glioblastoma treatment. Nat Commun. 2023;14:4557.","journal-title":"Nat Commun"},{"key":"3072_CR28","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1111\/j.1471-4159.2009.06027.x","volume":"109","author":"C Eckerich","year":"2009","unstructured":"Eckerich C, Schulte A, Martens T, Zapf S, Westphal M, Lamszus K. RON receptor tyrosine kinase in human gliomas: expression, function, and identification of a novel soluble splice variant. J Neurochem. 2009;109:969\u201380.","journal-title":"J Neurochem"},{"key":"3072_CR29","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1038\/sj.bjc.6602662","volume":"93","author":"T Maeda","year":"2005","unstructured":"Maeda T, Tashiro H, Katabuchi H, Begum M, Ohtake H, Kiyono T, et al. Establishment of an immortalised human ovarian surface epithelial cell line without chromosomal instability. Br J Cancer. 2005;93:116\u201323.","journal-title":"Br J Cancer"},{"key":"3072_CR30","first-page":"4956","volume":"61","author":"Y Sonoda","year":"2001","unstructured":"Sonoda Y, Ozawa T, Hirose Y, Aldape KD, McMahon M, Berger MS, et al. Formation of intracranial tumors by genetically modified human astrocytes defines four pathways critical in the development of human anaplastic astrocytoma. Cancer Res. 2001;61:4956\u201360.","journal-title":"Cancer Res"},{"key":"3072_CR31","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1083\/jcb.200408003","volume":"167","author":"PD Lu","year":"2004","unstructured":"Lu PD, Harding HP, Ron D. Translation reinitiation at alternative open reading frames regulates gene expression in an integrated stress response. J Cell Biol. 2004;167:27\u201333.","journal-title":"J Cell Biol"},{"key":"3072_CR32","doi-asserted-by":"crossref","unstructured":"Luger AL, Lorenz NI, Urban H, Dive I, Engel AL, Strassheimer F, et al. Activation of epidermal growth factor receptor sensitizes glioblastoma cells to hypoxia-induced cell death. Cancers. 2020;12:2144.","DOI":"10.3390\/cancers12082144"},{"key":"3072_CR33","doi-asserted-by":"publisher","first-page":"2623","DOI":"10.1093\/brain\/awx196","volume":"140","author":"AL Thiepold","year":"2017","unstructured":"Thiepold AL, Lorenz NI, Foltyn M, Engel AL, Dive I, Urban H, et al. Mammalian target of rapamycin complex 1 activation sensitizes human glioma cells to hypoxia-induced cell death. Brain. 2017;140:2623\u201338.","journal-title":"Brain"}],"container-title":["Cell Death Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41420-026-03072-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41420-026-03072-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41420-026-03072-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T08:26:11Z","timestamp":1775723171000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41420-026-03072-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,27]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3072"],"URL":"https:\/\/doi.org\/10.1038\/s41420-026-03072-4","relation":{},"ISSN":["2058-7716"],"issn-type":[{"value":"2058-7716","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,27]]},"assertion":[{"value":"27 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"JPS has received honoraria for presentations, educational events and advisory board participation from GSK, Boehringer Ingelheim, Roche, Novocure, Seagen, Servier and Med-Update. MWR has received a research grant from UCB as well as honoraria for advisory board participation from Alexion and Servier. J-BW, HU, BS, TB, A-CH, SLi, DN, LFH, J-HS, MdS, TR, A-LL, and SLe. report no disclosures relevant to the manuscript.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"181"}}